Adjuvant ribociclib (Kisqali) plus endocrine therapy showed a sustained reduction in recurrence risk beyond its initial 3-year treatment window, according to Sara A. Hurvitz, MD, FACP, who added that the ongoing separation of the Kaplan-Meier…
Adjuvant Ribociclib Plus AI Therapy Shows More Pronounced iDFS Benefit After 5 Years in HR+, HER2-Negative Early Breast Cancer
